BrainStorm Vows to Push for Adcomm Meeting on NurOwn in ALS

After receiving a Refusal to File (RTF) Letter regarding a BLA for NurOwn in ALS, BrainStorm Cell Therapeutics emphasized its commitment to seek an advisory committee meeting through a Type A meeting with the FDA.